WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H202042
CAS#: 475488-23-4
Description: NVP-ADW742, also known as ADW-742 or GSK 552602A, is a novel small weight molecular inhibitor of IGF-IR with potential anticancer activity. NVP-ADW742 inhibited IGF-IR-mediated proliferation with an IC50 of 11.12 µmol/l. NVP-ADW742 induced early suppression of Akt, P38 and GSK-3β phosphorylation. NVP-ADW742 enhanced the chemosensitivity of Daoy to temozolomide in vitro, as a potent anti-tumor agent highly selective against IGF-IR. NVP-ADW742 was found to suppresse survival and resistance to chemotherapy in acute myeloid leukemia cells.
Hodoodo Cat#: H202042
Name: ADW742
CAS#: 475488-23-4
Chemical Formula: C28H31N5O
Exact Mass: 453.25
Molecular Weight: 453.579
Elemental Analysis: C, 74.14; H, 6.89; N, 15.44; O, 3.53
Synonym: NVP-ADW742; NVP ADW-742; NVP ADW 742; ADW 742; ADW-742; ADW742; GSK 552602A; GSK-552602A; GSK552602A.
IUPAC/Chemical Name: 5-(3-(benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
InChi Key: LSFLAQVDISHMNB-AFARHQOCSA-N
InChi Code: InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)/t21-,23-
SMILES Code: NC1=C2C(N([C@H]3C[C@H](CN4CCCC4)C3)C=C2C5=CC=CC(OCC6=CC=CC=C6)=C5)=NC=N1
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | NVP-ADW742 (ADW742) is an IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM that also inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. |
| In vitro activity: | Dose-dependent blockade of basal and IGF1-induced phosphorylation was seen with ADW742 in all cell lines (IC50 of phosphorylation = 171-508 nmol/L). As shown in Fig. 1 and Supplementary Figs. S2-S4, the effects of this compound depended on the levels of IGF1R protein expression and basal phosphorylation of each cell line. Furthermore, AKT pathway activation induced by IGF1 was markedly blocked with the pretreatment with ADW742. Phospho-AKT and p-mTOR (Fig. 1C-D; Supplementary Figs. S2-4) were inhibited in a dose-dependent manner. Sensitivity to the drug showed a positive correlation with the levels of expression and basal phosphorylation of IGF1R. In contrast, MAPK42/44 remained active even when pretreated with high concentrations of ADW742, in all cell lines except A4573. Reference: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. https://clincancerres.aacrjournals.org/content/12/11/3532.long |
| In vivo activity: | The IGF1-receptor inhibitor NVP-ADW742 (500 μM) or its vehicle control, DMSO (5%), were intraperitoneally injected into zebrafish every 12 h throughout the eight day dark-adaptation period. NVP-ADW742 significantly reduced the number of proliferating cells in the ONL at 8 days of dark-adaptation relative to DMSO controls (Fig. 7A–E; NVP-ADW742: 5.8 ± 1.0, n = 21; DMSO: 10.4 ± 1.4, n = 33, p = 2.5*10−6). In contrast, the low number of INL PCNA-positive cells was not affected by exposure to NVP-ADW742 (NVP-ADW742: 0.13 ± 0.07, n = 21; DMSO: 0.23 ± 0.08, n = 33, p = 0.069). Taken together, these data suggest that dark-adaptation-mediated rod precursor cell proliferation occurred in an IGF1-receptor-dependent manner. Reference: Exp Eye Res. 2019 Jan;178:148-159. https://pubmed.ncbi.nlm.nih.gov/30267656/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.5 | 45.15 | |
| DMF | 30.0 | 66.14 | |
| Ethanol | 12.5 | 27.58 | |
| Ethanol:PBS (pH 7.2) (1:10) | 0.1 | 0.20 |
The following data is based on the product molecular weight 453.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778. PMID: 16740780. 2. Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005 Feb 15;11(4):1563-71. doi: 10.1158/1078-0432.CCR-04-1544. PMID: 15746061. 3. Lahne M, Piekos SM, O'Neill J, Ackerman KM, Hyde DR. Photo-regulation of rod precursor cell proliferation. Exp Eye Res. 2019 Jan;178:148-159. doi: 10.1016/j.exer.2018.09.015. Epub 2018 Sep 27. PMID: 30267656. 4. Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol. 2005 Nov 25;70(11):1685-96. doi: 10.1016/j.bcp.2005.08.020. Epub 2005 Oct 3. PMID: 16207485. |
| In vitro protocol: | 1. Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778. PMID: 16740780. 2. Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005 Feb 15;11(4):1563-71. doi: 10.1158/1078-0432.CCR-04-1544. PMID: 15746061. |
| In vivo protocol: | 1. Lahne M, Piekos SM, O'Neill J, Ackerman KM, Hyde DR. Photo-regulation of rod precursor cell proliferation. Exp Eye Res. 2019 Jan;178:148-159. doi: 10.1016/j.exer.2018.09.015. Epub 2018 Sep 27. PMID: 30267656. 2. Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol. 2005 Nov 25;70(11):1685-96. doi: 10.1016/j.bcp.2005.08.020. Epub 2005 Oct 3. PMID: 16207485. |
1: Zhou H, Rao J, Lin J, Yin B, Sheng H, Lin F, Zhang N, Yang L. The insulin- like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. Oncol Rep. 2011 Jun;25(6):1565-71. doi: 10.3892/or.2011.1233. Epub 2011 Mar 23. PMID: 21455580.
2: Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778. PMID: 16740780.
3: Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP- ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005 Feb 15;11(4):1563-71. doi: 10.1158/1078-0432.CCR-04-1544. PMID: 15746061.
4: He Y, Zhang J, Zheng J, Du W, Xiao H, Liu W, Li X, Chen X, Yang L, Huang S. The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncol Res. 2010;19(1):35-43. doi: 10.3727/096504010x12828372551821. PMID: 21141739.
5: Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther. 2004 May;3(5):527-35. PMID: 15141010.
6: Zong R, Chen X, Feng J, Xu S. IGF-1R depletion sensitizes colon cancer cell lines to radiotherapy. Cancer Biomark. 2021;32(2):199-206. doi: 10.3233/CBM-210016. PMID: 34092618.
7: Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Ucero ÁC, González-Barcala FJ, Salgado FJ, Pichel JG. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines. 2021 Jul 29;9(8):912. doi: 10.3390/biomedicines9080912. Erratum in: Biomedicines. 2022 Mar 22;10(4): PMID: 34440118; PMCID: PMC8389607.
8: Yamagishi A, Ikeda Y, Ikeuchi M, Yuki R, Saito Y, Nakayama Y. Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. Int J Mol Sci. 2020 Feb 5;21(3):1058. doi: 10.3390/ijms21031058. PMID: 32033461; PMCID: PMC7037296.
9: Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar;5(3):221-30. doi: 10.1016/s1535-6108(04)00050-9. PMID: 15050914.
10: Chablais F, Jazwinska A. IGF signaling between blastema and wound epidermis is required for fin regeneration. Development. 2010 Mar;137(6):871-9. doi: 10.1242/dev.043885. PMID: 20179093.
11: Lahne M, Piekos SM, O'Neill J, Ackerman KM, Hyde DR. Photo-regulation of rod precursor cell proliferation. Exp Eye Res. 2019 Jan;178:148-159. doi: 10.1016/j.exer.2018.09.015. Epub 2018 Sep 27. PMID: 30267656.
12: Morgan GJ, Krishnan B, Jenner M, Davies FE. Advances in oral therapy for multiple myeloma. Lancet Oncol. 2006 Apr;7(4):316-25. doi: 10.1016/S1470-2045(06)70657-X. PMID: 16574547.
13: Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz- Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1. PMID: 25081930.
14: Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ, Kurzman ID. RT-PCR- based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res. 2010 Feb;20(1):35-42. doi: 10.1097/CMR.0b013e328331ca86. PMID: 19949352.
15: Chen L, Zhu Z, Gao W, Jiang Q, Yu J, Fu C. Systemic analysis of different colorectal cancer cell lines and TCGA datasets identified IGF-1R/EGFR-PPAR- CASPASE axis as important indicator for radiotherapy sensitivity. Gene. 2017 Sep 5;627:484-490. doi: 10.1016/j.gene.2017.07.003. Epub 2017 Jul 4. PMID: 28687332.
16: Xie L, Tang Q, Yang L, Chen L. Insulin-like growth factor I promotes oocyte maturation through increasing the expression and phosphorylation of epidermal growth factor receptor in the zebrafish ovary. Mol Cell Endocrinol. 2016 Jan 5;419:198-207. doi: 10.1016/j.mce.2015.10.018. Epub 2015 Oct 24. PMID: 26599586.
17: Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):54-72. doi: 10.2174/157489209787002515. PMID: 19149688.
18: Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011 Sep 15;344(1-2):1-24. doi: 10.1016/j.mce.2011.07.002. Epub 2011 Jul 18. PMID: 21782884.
19: Catalano R, Giardino E, Treppiedi D, Mangili F, Morelli V, Elli FM, Serban AL, Luconi M, Mannelli M, Spada A, Arosio M, Mantovani G, Peverelli E. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. Cancer Lett. 2021 Jan 28;497:77-88. doi: 10.1016/j.canlet.2020.10.022. Epub 2020 Oct 16. PMID: 33075426.
20: Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol. 2005 Nov 25;70(11):1685-96. doi: 10.1016/j.bcp.2005.08.020. Epub 2005 Oct 3. PMID: 16207485.
